Journal of Neurology

, Volume 256, Issue 7, pp 1076–1082 | Cite as

Rituximab in cryoglobulinemic peripheral neuropathy

  • Roberto Cavallo
  • Dario Roccatello
  • Elisa Menegatti
  • Carla Naretto
  • Franca Napoli
  • Simone Baldovino
Original Communication

Abstract

Type II mixed cryoglobulinemia is sustained by an oligoclonal production of IgM sharing rheumatoid activity and can be associated with renal, cutaneous, rheumatologic or neurological manifestations. Peripheral neuropathy is a major cause of morbidity in hepatitis C virus-associated mixed cryoglobulinemia and is often refractory to any treatment. Rituximab induces a selective depletion of IgM-producing B cells, and both case reports on monoclonal IgM-related polyneuropathy as well as studies on small series of patients with interferon α-resistant mixed cryoglobulinemia have suggested that it may be beneficial. Thirteen patients affected by type II mixed cryoglobulinemia with polyneuropathy were treated. Rituximab was administered intravenously at a dose of 375 mg/m2 on days 1, 8, 15 and 22. Two more doses were given 1 and 2 months later. No other immunosuppressive drugs were added. Response was evaluated by assessing the changes in the clinical neurological condition, in electromyographic indices and in laboratory parameters (including cryocrit, viral load, complement levels and rheumatoid factor) over at least 12 months. Sensory symptoms disappeared or improved following treatment. A significant improvement in the clinical neuropathy disability score was observed. Electromyography examination revealed that the amplitude of compound motor action potential had increased. Viral load did not significantly change. Side effects were negligible. In this open prospective study, rituximab appeared to be effective and safe in the treatment of patients with type II cryoglobulinemia-associated neuropathy.

Keywords

HCV-related mixed cryoglobulinemia Cryoglobulinemic peripheral neuropathy Rituximab 

Notes

Acknowledgments

We would like to thank Sara Bonello, Roberto Del Mastro and Guido Lombardi for their assistance in performing electrophysiologic studies.

Conflict of interest statement

None.

References

  1. 1.
    Alpa M, Ferrero B, Cavallo R, Perna A, Naretto C, Gennaro M, Di Simone D, Bellizia L, Mansouri M, Rossi D, Modena V, Giachino O, Sena LM, Roccatello D (2007) Anti-GM1 and anti-sulfatide antibodies in patients with systemic lupus erythematosus, Sjögren’s syndrome, mixed cryoglobulinemia and idiopathic systemic vasculitis. Clin Exp Rheumatol 25(4):556–562PubMedGoogle Scholar
  2. 2.
    Ammendola A, Sampaolo S, Migliaresi S, Ambrosone L, Ammendola E, Ciccone G, Di Iorio G (2007) Autonomic neuropathy in mixed cryoglobulinemia. J Neurol 254(2):215–219PubMedCrossRefGoogle Scholar
  3. 3.
    Arzoo K, Sadeghi S, Liebman HA (2002) Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 61(10):922–924PubMedCrossRefGoogle Scholar
  4. 4.
    Benedetti L, Briani C, Grandis M, Vigo T, Gobbi M, Ghiglione E, Carpo M, Cocito D, Caporale CM, Sormani MP, Mancardi GL, Nobile-Orazio E, Schenone A (2007) Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 12:102–107PubMedCrossRefGoogle Scholar
  5. 5.
    Bonomo L, Casato M, Afeltra A, Caccavo D (1987) Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 83(4):726–730PubMedCrossRefGoogle Scholar
  6. 6.
    Boonyapisit K, Katirji B (2002) Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 25(6):909–913PubMedCrossRefGoogle Scholar
  7. 7.
    Briani C, Chemello L, Zara G, Ermani M, Bernardinello E, Ruggero S, Toffanin E, Gatta A, Battistin L, Cavalletto L (2006) Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. Neurology 67(5):781–785PubMedCrossRefGoogle Scholar
  8. 8.
    Broglio L, Lauria G (2005) Worsening after rituximab treatment in anti-MAG neuropathy. Muscle Nerve 32(3):378–379PubMedCrossRefGoogle Scholar
  9. 9.
    Cai FZJ, Ahern M, Smith M (2006) Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol 33(6):1197–1198PubMedGoogle Scholar
  10. 10.
    Chad D, Pariser K, Bradley WG, Adelman LS, Pinn VW (1982) The pathogenesis of cryoglobulinemic neuropathy. Neurology 32(7):725–729PubMedGoogle Scholar
  11. 11.
    Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T, Opolon P, Nguyen DT, Golliot F, Piette JC, Huraux JM, Lunel F (1999) Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 45(1):122–128PubMedCrossRefGoogle Scholar
  12. 12.
    Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, Lauletta G, Rizzi R (1994) Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84(10):3336–3343PubMedGoogle Scholar
  13. 13.
    Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, Urdea M, Sánchez-Pescador R (1996) Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 34(4):901–907PubMedGoogle Scholar
  14. 14.
    Ferri C, Mascia MT (2006) Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18(1):54–63PubMedGoogle Scholar
  15. 15.
    Gemignani F, Brindani F, Alfieri S, Giuberti T, Allegri I, Ferrari C, Marbini A (2005) Clinical spectrum of cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 76(10):1410–1414PubMedCrossRefGoogle Scholar
  16. 16.
    Khella SL, Frost S, Hermann GA, Leventhal L, Whyatt S, Sajid MA, Scherer SS (1995) Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy treatment with interferon alfa: case report and literature review. Neurology 45(3 pt 1):407–411PubMedGoogle Scholar
  17. 17.
    Koskinas J, Kilidireas C, Karandreas N, Kountouras D, Savvas S, Hadziyannis E, Archimandritis AJ (2007) Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study. Liver Int 27(3):414–420PubMedCrossRefGoogle Scholar
  18. 18.
    Lamprecht P, Moosig F, Gause A, Herlyn K, Csernok E, Hansen H, Gross WL (2001) Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis 60(4):385–390PubMedCrossRefGoogle Scholar
  19. 19.
    Levine TD, Pestronk A (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52(8):1701–1704PubMedGoogle Scholar
  20. 20.
    Lidove O, Cacoub P, Hausfater P, Wechsler B, Frances C, Leger JM, Piette JC (1999) Cryoglobulinemia and hepatitis C: worsening of peripheral neuropathy after interferon alpha treatment. Gastroenterol Clin Biol 23(3):403–406PubMedGoogle Scholar
  21. 21.
    Looney RJ (2002) Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 61(10):863–866PubMedCrossRefGoogle Scholar
  22. 22.
    Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R (1994) Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology 19(2):273–279PubMedCrossRefGoogle Scholar
  23. 23.
    Mariette X, Chastang C, Clavelou P, Louboutin JP, Leger JM, Brouet JC (1997) A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 63(1):28–34PubMedCrossRefGoogle Scholar
  24. 24.
    Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, Carniello G, Virgolini L, Tirelli U, Pozzato G (2005) Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42(5):632–638PubMedCrossRefGoogle Scholar
  25. 25.
    Nemni R, Sanvito L, Quattrini A, Santuccio G, Camerlingo M, Canal N (2003) Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry 74(9):1267–1271PubMedCrossRefGoogle Scholar
  26. 26.
    Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S (1998) Binding of hepatitis C virus to CD81. Science 282(5390):938–941PubMedCrossRefGoogle Scholar
  27. 27.
    Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, Shiffman ML, Minuk G, Reddy KR, Reindollar RW, Lin A, Brunda MJ (2004) Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 99(7):1298–1305PubMedCrossRefGoogle Scholar
  28. 28.
    Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, Steck AJ (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27(5):611–615PubMedCrossRefGoogle Scholar
  29. 29.
    Roccatello D, Mazzucco G, Coppo R, Piccoli G, Malavasi F, Cavalli G, Martina G, Amprimo MC, Guerra MG, Amore A (1991) Immune material processing by phagocyte cell system in cryoglobulinemia. Clin Nephrol 36(3):114–126PubMedGoogle Scholar
  30. 30.
    Roccatello D, Isidoro C, Mazzucco G, Mesiti A, Quattrocchio G, Amore A, Molino A, Coppo R, Sena LM, Piccoli G (1993) Role of monocytes in cryoglobulinemia-associated nephritis. Kidney Int 43(5):1150–1155PubMedCrossRefGoogle Scholar
  31. 31.
    Roccatello D, Morsica G, Picciotto G, Cesano G, Ropolo R, Bernardi MT, Cacace G, Cavalli G, Sena LM, Lazzarin A, Piccoli G, Rifai A (1997) Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinaemia and hepatitis C virus (HCV) infection. Clin Exp Immunol 110(1):9–14PubMedCrossRefGoogle Scholar
  32. 32.
    Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, Costanzo P, Giachino O, Mazzucco G, Sena LM (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19(12):3054–3061PubMedCrossRefGoogle Scholar
  33. 33.
    Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G, Confalonieri R, Tarantino A, Pasquali S, Amoroso A, Savoldi S, Colombo V, Manno C, Ponzetto A, Moriconi L, Pani A, Rustichelli R, Di Belgiojoso GB, Comotti C, Quarenghi MI (2007) Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49(1):69–82PubMedCrossRefGoogle Scholar
  34. 34.
    Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C, Di Simone D, Francica S, Cavallo R, Alpa M, Napoli F, Sena L (2008) Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 34(1):111–117PubMedCrossRefGoogle Scholar
  35. 35.
    Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101(10):3818–3826PubMedCrossRefGoogle Scholar
  36. 36.
    Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, Colasanti G, Damilano I, D’Amico G, Minetti L (1995) Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 47(2):618–623PubMedCrossRefGoogle Scholar
  37. 37.
    Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101(10):3827–3834PubMedCrossRefGoogle Scholar
  38. 38.
    Zaltron S, Puoti M, Liberini P, Antonini L, Quinzanini M, Manni M, Forleo MA, Rossi S, Spinetti A, Zanini B, Carosi G (1998) High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia. Ital J Gastroenterol Hepatol 30(4):391–395PubMedGoogle Scholar
  39. 39.
    Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, Sabo E, Tsykounov I, Naschitz JE, Yeshurun D (2000) Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 27(9):2172–2178PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Roberto Cavallo
    • 1
    • 2
  • Dario Roccatello
    • 2
    • 3
  • Elisa Menegatti
    • 3
  • Carla Naretto
    • 2
  • Franca Napoli
    • 2
  • Simone Baldovino
    • 2
    • 3
  1. 1.S.C. NeurologiaOspedale San Giovanni BoscoTurinItaly
  2. 2.Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare (CMID)Università di TorinoTurinItaly
  3. 3.Dipartimento di Medicina e Oncologia Sperimentale, Sezione Patologia ClinicaUniversità di TorinoTurinItaly

Personalised recommendations